A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as Monotherapy in Pediatric Subjects with New or Recent-Onset Epilepsy
Phase of Trial: Phase III
Latest Information Update: 26 Mar 2018
At a glance
- Drugs Topiramate (Primary) ; Levetiracetam
- Indications Epilepsy; Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions; Registrational
- Sponsors Janssen Research & Development; Janssen-Cilag
- 10 Jun 2017 Biomarkers information updated
- 20 Apr 2017 Planned End Date changed from 1 Mar 2018 to 26 Mar 2019.
- 28 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.